Use of a substance p antagonist in a pharmaceutical composition

Abstract

The invention relates to the use of a substance P antagonist for the preparation of a pharmaceutical composition, in particular for topical application, for treating lichens, prurigo, pruriginous toxicoderma and severe pruritus of neurogenic origin.

1 . Use of at least one substance P antagonist for the preparation of a pharmaceutical or dermatological composition for treating lichens, prurigo, pruriginous toxicoderma and severe pruritus of neurogenic origin.  
     
     
         2 . Use according to  claim 1 , characterized in that the substance P antagonist is chosen from peptides and compounds comprising at least one. heterocycle and nitrogen compounds comprising at least one benzene ring.  
     
     
         3 . Use according to  claim 1  or  2 , characterized in that the peptide is sendide or spantide II.  
     
     
         4 . Use according to  claim 1  or  2 , characterized in that the compound comprising at least one heterocycle is a heterocyclic nitrogen compound chosen from 2-tricyclyl-2-aminoethane derivatives, spirolactam derivatives, quinuclidine derivatives, azacyclic derivatives, aminopyrrolidine derivatives, piperidine derivatives, aminoazaheterocycles and isoindole derivatives.  
     
     
         5 . Use according to  claim 1  or  2 , characterized in that the compound comprising at least one heterocycle is a heterocyclic oxygen or sulphur compound chosen from furan derivatives, benzofuran derivatives, thiophene derivatives and benzothiophene derivatives, and in particular tetrazolylbenzofurancarboxamides or tetrazolylbenzothiophenecarboxamides.  
     
     
         6 . Use according to  claim 1  or  2 , characterized in that the nitrogen compound containing at least one benzene ring is an ethylenediamine derivative.  
     
     
         7 . Use according to any one of the preceding claims, characterized in that the substance P antagonist is used in an amount ranging from 0.000001 to 5% by weight relative to the total weight of the composition.  
     
     
         8 . Use according to any one of the preceding claims, characterized in that the substance P antagonist is used in an amount ranging from 0.0001 to 0.1% by weight relative to the total weight of the composition.  
     
     
         9 . Use according to any one of the preceding claims, characterized in that the composition is an aqueous, oily or aqueous-alcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a microemulsion, an aqueous gel, an anhydrous gel, a serum or a dispersion of vesicles, of microcapsules or of microparticles.  
     
     
         10 . Use according to any one of the preceding claims, characterized in that the composition contains at least one active agent chosen from proteins, protein hydrolysates, amino acids, polyols, urea, sugars, sugar derivatives, vitamins, starch, plant extracts, hydroxy acids, retinoids, essential fatty acids, ceramides, essential oils and salicylic acid and its derivatives.